Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT06968299
Recruiting Not applicable

Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological

NCT06968299 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-05-20
Last updated
2025-11-24

Condition(s) studied

Cognitive Functions Perceptual DisturbancesCognitive Function AbnormalSleepPsychological

Investigational drug(s) / intervention(s)

ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules

ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules: Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.

Study summary

This open-label, single-group, pre/post-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability. It is expected that 40 subjects aged 18 years and above will be recruited, with a target of 30 cases, to take ExoBDNF probiotics for a total of 8 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subjects must be volunteers who are 18 years of age or older, mentally clear and able to communicate. 2. Subjects who agree to participate in this trial and voluntarily sign the trial consent form. Exclusion Criteria: 1. Subjects who are expected to be or have been confirmed to be pregnant (medical history). 2. Subjects with gallbladder disease, gastrointestinal disease, gout, porphyria, or a history of gastric weight control surgery. 3. Subjects with high blood pressure (≥160/100 mmHg after resting for 10 minutes) or taking diuretics. 4. Subjects with heart disease, hepatorenal insufficiency, hyperthyroidism or hypothyroidism, Cushing's syndrome, malignant tumors, or any other disease that may affect the results of the study. 5. Subjects with severe hearing or visual impairment that makes it impossible to perform examinations and assessments. 6. Subjects with any history of brain surgery, penetrating, neurovascular, infectious or other severe brain injury, epilepsy or other major neurological abnormalities, such as traumatic brain injury with loss of consciousness for more than 24 hours, or memory loss after head trauma for more than 7 days were excluded. 7. Subjects with intellectual disabilities. 8. Subjects who had consumed probiotics or were expected to consume probiotics within 2 weeks before the screening visit. 9. Subjects who had participated in or were expected to participate in clinical trials within 4 weeks before the screening visit.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tri-Service General Hospital, National Defense Medical Center Taipei Taiwan Recruiting

More SunWay Biotech Co., LTD. trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06968299 on ClinicalTrials.gov ↗ ← All trials in Taiwan